Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8790985 | 1.00 | BTN3A1 (0.33) | BTN3A1ELANETSHRMRGPRX4MEN1 | |
| SCHEMBL2750626 | 0.88 | BTN3A1 (0.35) | BTN3A1TSHRMEN1KMT2A | |
| SCHEMBL1455705 | 0.86 | ALDH1A1 (0.31) | TSHR | |
| SCHEMBL12617873 | 0.86 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL8791075 | 0.83 | TSHR (0.37) | TSHRMRGPRX4MEN1KMT2A | |
| SCHEMBL30392886 | 0.82 | — | — | |
| SCHEMBL1455707 | 0.80 | INPPL1 (0.33) | — | |
| SCHEMBL29572668 | 0.79 | CETP (0.38) | TSHRMRGPRX4MEN1KMT2A | |
| SCHEMBL8791231 | 0.79 | SRC (0.36) | TSHRMRGPRX4MEN1KMT2A | |
| SCHEMBL1462554 | 0.79 | CETP (0.38) | TSHRMRGPRX4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025045772-A1 | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-YL DERIVATIVES | COMPASS PATHFINDER LIMITED (GB) | 2025-03-06 | — | — | WO | disclosed |
| US-20250066394-A1 | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES | COMPASS PATHFINDER LIMITED (GB) | 2025-02-27 | — | — | US | disclosed |
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066394-A1 | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES | HTR2C, HTR2A, HTR3A | BTN3A1 4261/4885ELANE 3380/4885TSHR 126/4885 |
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | BTN3A1 2486/4885ELANE 2257/4885TSHR 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.